anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1.A polyclonal antibody, or its fragment, with reactivity against an anti-TCR Vbeta antibody and epitope of linking GPI. 2. A monoclonal antibody or its fragment with reactivity against an anti-TCR Vbeta antibody and epitope of linking GPI. 3. A peptide, which is not an anti-TCR Vbeta antibody, with reactivity against an anti-TCR Vbeta antibody and epitope of linking GPI, and having sequence SEQ ID NO: 2. 4. Nucleinic acid, encoding peptide according to claim 3, and having sequence SEQ ID NO: 1. 5. Vector comprising nucleinic acid according to claim 4. 6. Culture of eukaryotic host-cell, transformed by vector according to claim 5. 7. Culture of procariotic host-cell, transformed by vector according to claim 5. 8. Use of antibody according to claim 1 or 2, as a pharmaceutical or as a diagnostic agent. 9. Use of peptide according to claim 3, as a pharmaceutical or as a diagnostic agent. 10. Use of an antibody according to claim 1 or 2 in the manufacture of a medicament for the treatment of IDDM, NIDDM, or organ or non-organ specific autoimmune disease, cardiovascular disease, cancer cachexia and cancer or any other diseases where anti-phospholipid antibodies and/or hyperinsulinaemia and diseases and insulin resistance are present. 11. Use of polypeptide according to claim 3 in the manufacture of a medicament for the treatment of IDDM, NIDDM, or organ or non-organ specific autoimmune disease, cardiovascular disease, cancer cachexia and cancer or any other diseases where anti-phospholipid antibodies and/or hyperinsulinaemia and diseases and insulin resistance are present. 12. Composition comprising an effective amount of antibody according to claims 1 or 2, in conjunction with a acceptable carrier. 13. Composition comprising an effective amount of peptide according to claims 1 or 2, in conjunction with a acceptable carrier. 14. A method of treatment of disease, concerned with anti-phospholipid antibodies and/or hyperinsulinaemia and insulin resistance of mammalian, comprising the administration for needy mammalian of effective amount of antibody according to claims 1 or 2. 15. A method of treatment of disease, concerned with anti-phospholipid antibodies and/or hyperinsulinaemia and insulin resistance of mammalian, comprising the administration for needy mammalian of effective amount of peptide according to claims 3. 16. A method of treatment of disease, concerned with anti-phospholipid antibodies and/or hyperinsulinaemia and insulin resistance of mammalian, comprising the administration for needy mammalian of effective amount of composition according to claim 12. 17. A method of treatment of disease, concerned with anti-phospholipid antibodies and/or hyperinsulinaemia and insulin resistance of mammalian, comprising the administration for needy mammalian of effective amount of composition according to claim 13. 18. A method for detection of a naturally-occurring autoantibody in body fluid, comprising providing of contact of said body fluid with antibody according to claims 1 or 2 and with target molecules and assessing the amount of said autoantibody that binds specifically to the target molecule.
PURPOSE:To promote the induction of a new bone and to enhance bone inducing capacity, by combining the collagen and bone forming proteinaceous factor present in a living body with a foamed composition of a calcium phosphate compound having good bio-compatibility. CONSTITUTION:A curing liquid is mixed and kneaded with a powder obtained by adding bicarbonate to a calcium phosphate compound to mix both of them and the resulting mixture is molded into a desired shape. This foamed composition is formed by dipping the molded one in a buffer solution of collagen and/or B.M.P. (bone forming proteinaceous factor). When collagen is adsorbed and bonded between the foamed composition and B.M.P., the foamed composition is dipped in a collagen solution and subsequently dipped in a B.M.P. buffer solution to establish a foothold for bone induction. The adsorption and bonding method of collagen and/or B.M.P. may be performed by coating or spraying other than dipping. The exposure degree of calcium phosphate, collagen and B.M.P. to the surface of the foamed composition may be appropriately selected corresponding to the adaptation region of a living body.
BACKGROUND: To investigate the correlation between microinvasion and various features of hepatocellular carcinoma (HCC), and to clarify the microinvasion distance from visible HCC lesions to subclinical lesions, so as to provide clinical basis for the expandable boundary of clinical target volume (CTV) from gross tumor volume (GTV) in the radiotherapy of HCC.
METHODS: HCC patients underwent hepatectomy of liver cancer in our hospital between July 2019 and November 2021 were enrolled. Data on various features and tumor microinvasion distance were collected. The distribution characteristics of microinvasion distance were analyzed to investigate its potential correlation with various features. Tumor size compared between radiographic and pathologic samples was analyzed to clarify the application of pathologic microinvasion to identify subclinical lesions of radiographic imaging.
RESULTS: The average microinvasion distance was 0.6 mm, with 95% patients exhibiting microinvasion distance less than 3.0 mm, and the maximum microinvasion distance was 4.0 mm. A significant correlation was found between microinvasion and liver cirrhosis (P = 0.036), serum albumin level (P = 0.049). Multivariate logistic regression analysis revealed that HCC patients with cirrhosis had a significantly lower risk of microinvasion (OR = 0.09, 95%CI = 0.02 ~ 0.50, P = 0.006). Tumor size was overestimated by 1.6 mm (95%CI=-12.8 ~ 16.0 mm) on radiographic size compared to pathologic size, with a mean %Δsize of 2.96% (95%CI=-0.57%~6.50%). The %Δsize ranged from - 29.03% to 34.78%.
CONCLUSIONS: CTV expanding by 5.4 mm from radiographic GTV could include all pathologic microinvasive lesions in the radiotherapy of HCC. Liver cirrhosis was correlated with microinvasion and were independent predictive factor of microinvasion in HCC.
This group will participate in activity-based measures employed in routine occupational and physical therapy practice to assess participants' wheelchair speed, maneuverability, and endurance. These measures include: the Life Space Assessment Scale, 6-Minute Push Test, Forward Push Test, Wheelchair Slalom Test, Craig Handicap Assessment and Reporting Technique, and PART-O.
The invention discloses a medicine for preventing and treating fowl pox. The traditional Chinese medicine is prepared from the following traditional Chinese medicines in a certain proportion: lithospermum, buffalo horn, cimicifuga foetida, cicada slough, folium isatidis, great burdock achene, honeysuckle, schizonepeta, mint, rheum officinale, cape jasmine, dandelion and liquorice. Pulverizing the above materials, grinding, mixing, and stirring. In clinical application, the medicine is soaked in boiling water for 30-60 minutes, so that the effective components of the medicine are fully dissolved and separated out, the absorption in the body of a sick chicken is facilitated, and meanwhile, a little sugar and Vc are added, so that the medicine effect can be improved. The medicine has high clinical cure rate, no adverse reaction, no medicine residue and no hidden danger of drug resistance. The preparation method is simple, the use is convenient, and the preparation method can be widely applied to the chicken industry.
The short and long-term benefits of breastfeeding to both the mother and infant are well established. Benefits for the child range from protection against common childhood infections, decreased rates of type-2 diabetes and systolic hypertension, lower rate of sudden infant death syndrome, increased performance on intelligence tests, and possible reduction in obesity. Maternal benefits include a reduction in the risk of breast cancer, diabetes, hyperlipidemia, hypertension, myocardial infarction, obesity, and ovarian cancer. Given this evidence the World Health Organization (WHO) and the American Academy of Pediatrics recommend, exclusive breastfeeding of infants for the first six months. WHO goes on to recommend breastfeeding to 2 years and beyond if mutually agreeable to both the mother and child. Despite these benefits and recommendations, according to the Centers for Disease Control and Prevention (CDC) in the United States 81% of infants were started breastfeeding and only 51% continued at 6 months. Perceived or actual low milk supply is one of the most common reasons for discontinuing breastfeeding.

This protocol is designed to investigate scientifically our current osteopathic standard of care. There is no available research data to date specifically on using osteopathic manipulation as an intervention to increase milk supply in lactating women.
1. Technical Result Increase in efficiency of treatment of endometriosis or infertility. 2. Essence The use of β-adrenergic agonist and pharmaceutical composition containing pharma-ceutically acceptable bioadhesive carrier for treatment of endometriosis or infertility, and for improving fertility. The use of said compositions provides therapeutically sufficient levels of the β-adrenergic agonist in blood and consequently minimizing or avoiding adverse side effects 3. Field of Application Medicine. Tables: 3
The use of an invasive strategy for the management of NSTEMI according to estimated risk of 6 month mortality is recommended by international guidelines. NSTEMI appropriate for coronary angiography (and percutaneous intervention) have better outcomes compare with NSTEMI who are medically managed. Whilst the national and international guidelines recommend that the timing of (in-hospital) coronary angiography (\<24, 24-72, 72-96 and \<96 hours) is based upon estimated clinical risk (using the GRACE risk score) there is scientific and clinical uncertainty as to the incremental benefit that more urgent invasive treatments strategies have over and above that of delayed strategies. Moreover, the investigators recent research has shown that in the UK, may NSTEMI (eligible) for coronary angiography fail to achieve care according to the recommended time thresholds, and this is associated with potentially avoidable premature death.

This study aims to investigate the extent to which the time to angiography impacts on survival in patients hospitalised with NSTEMI. It will characterise patients according to their estimated risk of death, their time to angiography, and associated outcomes. The investigators anticipate that this observational study will provide Level B evidence for the benefits of the timing of an invasive strategy according to the GRACE risk score. The investigators are aware that the NICE guidelines for the management of acute chest pain are to be updated in 2016.
A soft, flexible, silicone pessary, purchased from the manufacturer (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix by 4 senior clinicians, who had experienced with pessary used, within one week of randomisation. Size of the pessary will be determined at the time of speculum inspection.
Briefly, the protocol will begin with pre-study determination of diuretic response at the screening visit via administration of 10 mg IV bumetanide and measuring peak FENa. Participants may proceed to the subsequent study procedures. Participants will begin a study diet provided by the metabolic kitchen five days prior to Day 0. Beginning on day 0, participants will take either NH4Cl or placebo 75mmol twice daily. On day 1, the participant will return to study site and receives the first dose of their twice daily study medication as well as their regular loop diuretic dose given as IV bumetanide, followed by completion of the biospecimen collection protocol and a 24-hour urine collection. On day 2, participants will receive a full 150mmol dose at Hr-2 (75 mmol if pH\<7.3-7.25, no NH4Cl if pH\<7.25). 2 hours after the IV bumetanide is given, 100mmol of sodium bicarbonate in 750ml of 5% dextrose will be administered to participants that received NH4Cl or 750 ml of lactated Ringer's solution to participants that received placebo (provided blinded by the investigational pharmacy).

After this visit, a washout period will be conducted before the above procedures are repeated with the alternate study medication. The washout period will be a minimum of 10 days and a maximum of 28 days. Five days prior to the end of the washout period, the participant will resume the study diet until the end of the study on day 18. On day 16, the participant will be crossed over to the alternate therapy (NH4Cl or placebo). On day 17, the participant will complete the same procedures as day 1 of the first arm. On day 18, the participant will complete the same procedures as day 2 of the first arm.

The administration of Bendroflumethiazide will occur under a separate ancillary protocol
A topical composition is provided in the form of a serum, lotion, cream, salve or gel, for use in the treatment of psoriasis in a patient. The composition comprises: (a) about 75 wt% to about 99 wt% of a C10-C30 carboxylic acid cholesterol/lanosterol ester mixture, based upon the weight of the composition less any solvent that may be present with a boiling point of 150°C or less. The composition also comprises (b) about 0.1 wt% to about 15 wt% of a penetration enhancer selected from the group consisting of oleyl alcohol, lauryl alcohol, isopropyl myristate, oleyl oleate, levulinic acid, glycerol monooleate, methyl laurate, sorbitan monooleate, triacetin, cetyl alcohol, cetyl lactate, dimethyl isosorbide, dipropylene glycol, ethyl hexyl lactate, glycolic acid, lauramine oxide, lauryl betaine, lauryl lactate, lauryl laurate, isopropyl pamitate, myristyl alcohol, myristal lactate, octyl salicylate, oleamine oxide, oleic acid, oleyl betaine, salicylic acid, stearyl alcohol, stearyl lactate, triethanolamine triacetate and combinations thereof. The composition further comprises (c) about 0.1 wt% to about 10 wt% of a water-insoluble film-forming/polymeric agent selected from the group consisting of polyalkenes, oleophilic copolymers of vinylpyrrolidone, acrylic copolymers, polyethylene glycol derivatives, polyolefins, polyurethanes and mixtures thereof. About 0 wt% to about 10 wt%  of an antioxidant (d) are provided in the composition, along with (e) about 0 wt% to about 10 wt% of a preservative selected from the group consisting of propyl paraben, methyl paraben, benzyl alcohol, benzalkonium chloride, tribasic calcium phosphate and phenoxyethanol or acids, and (f) about 0 to about 25 wt% of a vitamin. The treatment regimen consists of a topical administration of the composition to a psoriatic area of the patient at least once a day.
Breast cancer is among the most common malignancies in women in the United States. Over the years breast cancer management have dramatically developed from the extensive surgical approach toward the breast conservative approach. This was mainly due to the introduction of chemotherapy and hormonal therapy. Hormonal therapy in particular has been shown to improve the oncological outcomes of the breast cancer. However, while this is well documented in the clinical outcomes. Little is known in regards what happens on the genetic level. As such in this study the investigators would like to study the genetic and molecular outcomes that results after a short term neoadjuvant hormonal therapy on patients with breast cancer.

The hypothesis of this study is that short-term, preoperative hormonal treatment will induce genetic changes associated with reduced proliferation, including lower Ki67 expression, and changes in Estrogen Receptor (ER) and Progesterone Receptor (PR) expression. The data from such investigation will be very helpful in advancing the individualized care to women with breast cancer.
Consented subjects randomized to one of four doses of rocuronium will be transported to the operating room and be connected to routine monitors that included a BIS (Covidien), M-Entropy sensor (GE Healthcare) and TOF (train of four) monitor. Following preoxygenation, general anesthesia will be induced with propofol and remifentanil using traditional syringe pumps. The induction doses given and subsequent infusion rates will be determined by utilizing pharmacokinetic (Pk) models (Marsh model for propofol, Minto model for remifentanil). Unconsciousness will be confirmed by performing the usual clinical assessments and by obtaining a BIS value between 40 and 50. Once the subject is unconsciousness, they will be given the assigned dose of rocuronium, after which the study anesthesiologist will perform a laryngoscopy. The anesthesiologist performing the laryngoscopy will not know what dose of rocuronium the subject received. Neuromuscular blockade (NMB) will be monitored by a train-of-four twitch monitor (TOF Watch-SX) at the adductor pollicis muscle (2 HZ, 50mAmp) every 15 seconds.

At three minutes after the rocuronium administration, a standardized 20-second laryngoscopy will be applied. The CVI, entropy, and hemodynamic responses (heart rate, blood pressure measurement each minute) and train-of-four measurements will be monitored for three minutes before and after the laryngoscopy.
By conforming to ingroup norms, individuals coordinate with other group members, preserve cohesion, and avoid costs of exclusion. Previous experiments have shown that increased concerns about infectious disease increase conformity. However, coordination with other group members has multiple benefits, most of which exist independent of pathogenic infection. Hence, a strong causal effect of pathogen avoidance motivations on conformity seems unlikely. Results from five experiments (N = 1,931) showed only limited support for the hypothesis that experimentally increasing pathogen avoidance motivations influences conformity. Overall, our findings are not consistent with the notion that the human mind contains a fast-acting psychological mechanism that regulates conformity as a function of short-term pathogen avoidance motivations.
Patients apply cannabidiol cream topically to affected areas BID for 14 days. Patients then apply placebo cream topically to affected areas BID for 14 days.
Nal-IRI 80 mg/m2 administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hrs on days 1-3. Each cycle consists of 14 days. Treatment will be repeated every 2 wks.
This is a Phase 1, open-label (all people know the identity of the intervention), single dose study in 6 healthy adult male participants to characterize the absorption, metabolism and excretion of 14C-JNJ-63623872. The total study duration will be approximately of 16 days per participant. The study consists of 3 parts: Screening (that is, 28 days before study commences on Day 1); open-Label Treatment Phase(that is, Day 1); and Follow-up (that is, up to Day 16). All the eligible participants will receive 14C-JNJ-63623872 at a dose level of 600 milligram. Participants will enter the study site on Day -1 and stay at the study site at least until Day 8. Urine, feces, whole blood samples, plasma, nasal mucus and saliva samples will be collected up to Day 8. Unchanged JNJ-63623872 will be determined in plasma and, if feasible, in saliva. Participants' safety will be monitored throughout the study.
The present invention relates to various aspects of a procedure for reducing the carbon dioxide content of blood during treatment of a patient. A first aspect of the invention relates to a buffer solution for reducing the carbon dioxide content of blood when treating a patient suffering from pulmonary insufficiency or complete failure of pulmonary function, wherein the fluid is in gas exchange with a portion of the patient's blood being transported through an extracorporeal circuit. The first aspect of the invention also relates to an apparatus for extracorporeal reduction of the carbon dioxide content of blood using said buffer solution. A second aspect of the invention relates to a system for extracorporeal blood treatment also using the buffer solution and the apparatus, and to a treatment apparatus for extracorporeal blood treatment comprising the above-mentioned system. A third aspect of the invention relates to a functional unit for performing an extracorporeal blood treatment, a blood guiding apparatus for interacting with a functional unit for performing an extracorporeal blood treatment using a buffer solution as described above, the blood guiding apparatus comprising a blood treatment element, wherein the blood treatment element is an apparatus as described above for extracorporeal reduction of the carbon dioxide content of blood. In a fourth aspect, the invention relates to a therapeutic system comprising an apparatus for extracorporeal reduction of the carbon dioxide content of blood as described above and a balancing device. In a fifth aspect, the invention relates to a therapeutic system comprising an apparatus for extracorporeal reduction of the carbon dioxide content of blood as described above and means for reducing the pressure of a buffer solution as described above used in said therapeutic system.
Patients review educational material and resources via online STAND-T platform. Patients also receive interactive text messages for 3 months.
The procedures were performed at outpatient clinic without anesthesia. Lyophilized 100 IU BT Type-A (BOTOX, Alergan, CA, USA) was applied after diluted with 1 cc saline. A 26-G injector was used to inject 25 unit toxin in every 4 quadrants, to the alignment of clock 12, 3, 6, and 9 to internal anal sphincters.
An auto-controlled release type insulin formulation comprises glucose soluble polymer gel matrix in which insulin  is  inserted. The glucose soluble polymer gel matrix is prepared by  reacting  a boric acid deriv. polymer with a diol compound as  a  crosslinking agent. The   diol   compound   is   a   natural    disaccharide, oligosaccharide,  alkane  disaccharide  or   alkane   bisdihydroxy compound. The boric acid deriv. is N-acrylamido phenyl boric acid, carboxyphenyl boric acid, hydroxy phenyl boric acid, nitro  phenyl boric acid, amino nitro phenyl boric  acid,  ureido  phenyl  boric acid, ethane boric acid, propare boric acid  or  3-methyl-1-butane boric acid.
Arm A (NMES followed by IPC). Following baseline blood flow measurements using ultrasound, the neuromuscular electrostimulation (NMES) device will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The NMES device will be removed. After a 30 minute rest period, the intermittent pneumatic compression (IPC) device will be fitted, activated for 10 minutes and then blood flow measurements repeated.
A composition comprising starch, baking soda and a conditioning agent. The constituents, in proportions by weight based on the total weight of the composition may be as follows, 0.5 to 15% baking soda, 3 to 20% of a conditioning agent and the balance being starch. The composition may also include a fragrance. The composition may be in the form of a dry powder and may be used as a dry shampoo for the cleansing of soiled or greasy hair. The composition can also be used to clean the skin in the same dry formulation form. The composition is particularly useful on sensitive and/or young skin i.e., young children.